Page 1

EX - 99.1 2 earningsreleaseex991 - fy21x.htm EX - 99.1 Catalent Earnings Release Investor Contact : Catalent , Inc. Paul Surdez 732-537-6325 investors@catalent.com Exhibit 99.1 • • • Catalent , Inc. Reports Second Quarter Fiscal 2021 Results Q2'21 net revenue of $ 910.8 million increased 26 % as - reported , or 24 % in constant currency , compared to Q2'20 . Organic , constant currency net revenue grew 17 % , compared to Q2'20 . Q2'21 net earnings of $ 88.4 million increased 94 % , or 88 % in constant currency , compared to Q2'20 . Q2'21 Adjusted EBITDA of $ 223.5 million increased 31 % as - reported , or 28 % in constant currency , compared to Q2'20 . • Q2'21 Biologics segment net revenue of $ 403.9 million increased more than 75 % , compared to Q2'20 . • Increasing guidance to reflect projected net revenue growth of 23-28 % and Adjusted EBITDA growth of 26-33 % , compared to projected net revenue growth in previous guidance of 16-22 % and Adjusted EBITDA growth of 17-26 % . -- Somerset , N.J. - February 2 , 2021 Catalent , Inc. ( NYSE : CTLT ) , the leading global provider of advanced delivery technologies , development , and manufacturing solutions for drugs , biologics , cell and gene therapies , and consumer health products , today announced financial results for the second quarter of fiscal 2021 , which ended December 31 , 2020 . “ Our second quarter results reflect robust organic growth in our Biologics segment , and our increased guidance reflects our expectation of continued strong results for these offerings for the remainder of our fiscal year . Additional capacity in our drug product and drug substance offerings will come on line in the second half of our fiscal year to help fight the pandemic and serve other critical patient needs , ” said John Chiminski , Chair and Chief Executive Officer of Catalent , Inc. Second Quarter 2021 Consolidated Results Net revenue of $ 910.8 million increased 26 % as reported , or 24 % in constant currency , from the $ 721.4 million reported for the second quarter a year ago . Overall organic revenue growth ( i.e. , excluding the effect of acquisitions ) was 17 % . Net earnings were $ 88.4 million . Accounting for the net earnings attributable to holders of Catalent's Series A convertible preferred stock , net earnings attributable to common shareholders were $ 76.6 million , or $ 0.46 per basic share , compared to net earnings attributable to common shareholders of $ 34.3 million , or $ 0.23 per basic share , in the second quarter a year ago . 1